Pacific Bio (PACB) Reports In-Line Q1 EPS, Achieves Second Development Milestone
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Pacific Biosciences Achieves Second Development Milestone in Clinical Diagnostics Agreement With Roche
May 5, 2015 4:03 PM EDTMENLO PARK, Calif., May 5, 2015 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB), provider of the PacBio® RS II Sequencing System, today announced that it has achieved a second development milestone under its development, commercialization and license agreement with F. Hoffman-La Roche Ltd (Roche), earning an additional $10 million.
The development, commercialization and license agreement with Roche covers diagnostic products for clinical use, including sequencing systems and consumables based on Pacific Biosciences' Single Molecule, Real-Time (SMRT®) technology. Under the agreement, Roche has the exclusive right to commercialize and sell the developed diagnostic... More
Pacific Biosciences of California, Inc. Announces First Quarter 2015 Financial Results
May 5, 2015 4:03 PM EDTMENLO PARK, Calif., May 5, 2015 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB) today reported a 52% increase in revenue with $17.6 million for the first quarter ended March 31, 2015, compared to $11.6 million for the first quarter of 2014.
First quarter 2015 revenue includes product and service revenue of $14.0 million and $3.6 million quarterly amortization from the upfront Roche payment, while first quarter 2014 revenue includes product and service revenue of $9.9 million and $1.7 million quarterly amortization from the upfront Roche payment. The revised revenue recognized for the first quarter ended March 31, 2015 reflects the new amortization schedule resulting from increasing... More
